Working of Patents in India - Section 83, Form 27

Few obligations in Indian patent law are as frequently misunderstood, as consistently neglected and as consequential in their implications as the requirement to work a patent in India. The Patents Act, 1970 does not treat the grant of a patent as the end of the patentee’s obligations to the public it treats it as the beginning of a set of responsibilities that run for the life of the patent and whose non-performance carries serious legal consequences. At the heart of this framework is a legislative philosophy that is distinctly and deliberately Indian: that a patent is not merely a private property right granted for the benefit of its holder, but a social contract between the inventor and the public, under which the inventor receives a time-limited monopoly in exchange for two distinct obligations the disclosure of the invention to the public through the specification and the working of the invention for the benefit of the public through its commercial exploitation in the territory of India. The first of these obligations is enforced through the specification requirements of Section 10. The second is enforced through the working provisions of Chapter XVI of the Patents Act, the statement of working obligation under Section 146, the Form 27 filing requirement and ultimately through the compulsory licensing mechanism under Section 84 and the licence of right and revocation provisions that follow from non-working.

Understanding the working of patents framework in India requires engagement with Section 83, which articulates the general principles governing the working of patented inventions; Section 146, which imposes the mandatory obligation to file statements of working; Form 27, the prescribed form through which those statements are filed; the consequences of non-working and non-filing that range from compulsory licensing to revocation; and the body of case law and administrative practice that has given content to these provisions over the decades since the Patents Act came into force. This framework is not a peripheral aspect of Indian patent law. It is central to India’s approach to the patent system and to the balance that the Act strikes between the rights of patent holders and the interests of the public a balance that has been at the heart of India’s engagement with international IP obligations since the TRIPS Agreement came into force.

Section 83 The General Principles of Working

Section 83 of the Patents Act, 1970 sets out the general principles that the legislature considers should govern the working of patented inventions in India. It provides that patents are granted to encourage inventions and to secure that the inventions are worked in India on a commercial scale and to the fullest extent that is reasonably practicable without undue delay. It further provides that patents are not granted merely to enable patentees to enjoy a monopoly for the importation of the patented article and that the protection and enforcement of patent rights should contribute to the promotion of technological innovation and to the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare.

Section 83 is not a provision that creates directly enforceable rights or obligations in the manner of a specific statutory duty. It is a statement of legislative policy a declaration of the purposes for which the patent system exists and the principles by which it is to be administered. However, its significance in Indian patent law extends well beyond its status as a policy statement. It provides the interpretive framework within which the specific working obligations and compulsory licensing provisions of the Act are understood and applied. When the Controller of Patents adjudicates a compulsory licence application under Section 84, when the courts assess whether a patent has been adequately worked and when policy makers evaluate proposals for reform of the patent system, Section 83 is the touchstone against which the analysis is conducted.

The principle articulated in Section 83 that patents are not granted merely to enable patentees to enjoy a monopoly for the importation of the patented article is of particular practical significance. It directly establishes that mere importation of a patented product into India without any local manufacture does not constitute working of the patent in India for the purposes of the Act. This principle was authoritatively confirmed by the Intellectual Property Appellate Board in Bayer Corporation v. Natco Pharma Ltd. the compulsory licence case discussed further below where the IPAB held that working a patent in India requires domestic manufacture and that a patentee who satisfies the Indian market entirely through imports has not worked the patent in India within the meaning of the Act, regardless of the volume of sales achieved. This interpretation has significant implications for multinational pharmaceutical and technology companies who hold Indian patents but choose to supply the Indian market through imports rather than local manufacturing.

The reference in Section 83 to the promotion of technological innovation and the transfer and dissemination of technology reflects India’s TRIPS-informed understanding of the patent system as an instrument of development policy as well as a mechanism for the protection of private rights. TRIPS Article 7, which articulates the objectives of the TRIPS Agreement, uses almost identical language protection and enforcement of intellectual property rights should contribute to the promotion of technological innovation and to the transfer and dissemination of technology. India’s incorporation of this language into Section 83 signals a deliberate alignment of domestic patent policy with the development-oriented objectives articulated in TRIPS and a clear statement that the Indian patent system is designed to serve those objectives, not merely to protect the commercial interests of patent holders.

Section 146 The Obligation to File Statements of Working

Section 146 of the Patents Act imposes a mandatory obligation on every patentee and every licensee exclusive or otherwise to furnish statements as to the extent to which the patented invention has been worked on a commercial scale in India. This obligation is not contingent on a request from the Controller or on the initiation of any proceeding it is a self-executing duty that arises automatically and must be fulfilled by every person who holds or works a patent in India. Section 146(2) provides that every patentee and every licensee shall furnish to the Controller, within three months after the end of each financial year, a statement giving the extent to which the patented invention has been worked on a commercial scale in India during that financial year.

The obligation under Section 146 is independent of whether the patent is being actively enforced, whether the patent is subject to any opposition or revocation proceedings and whether the patentee considers the patent commercially significant. It attaches to every granted patent that is in force and it continues for every financial year during which the patent remains in force. A patentee who holds a portfolio of Indian patents whether actively commercialised, licensed or held for strategic purposes must file a Form 27 statement for every patent in the portfolio for every financial year in which it is in force.

The consequences of failing to comply with the Section 146 obligation are significant. Section 122 of the Patents Act provides that any person who refuses or fails to supply any information required under Section 146 or furnishes information that is false and which he either knows or has reason to believe to be false or does not believe to be true shall be punishable with fine which may extend to ten lakh rupees. This is a criminal sanction non-compliance with the Form 27 obligation is not merely an administrative irregularity but a statutory offence carrying a financial penalty. The seriousness with which the legislature treats this obligation reflects the central importance that the working requirement occupies in the Indian patent system’s design.

Form 27 The Statement of Working

Form 27 is the prescribed form under the Patents Rules, 2003 through which the Section 146 obligation is discharged. It requires the patentee or licensee to provide information about the patent’s working status in India during the relevant financial year. The form underwent significant revision following the Patents (Amendment) Rules, 2016 and the current version of Form 27 requires disclosure of considerably more detailed information than its predecessor.

The current Form 27 requires the applicant to identify the patent number and the financial year to which the statement relates. It requires a statement of whether the patent has been worked in India during the relevant financial year or has not been worked. Where the patent has been worked, the form requires disclosure of the quantum and value in Indian rupees of the patented product manufactured in India, the quantum and value of the patented product imported into India from other countries, the licenses and sublicenses granted during the year and a statement of whether the public requirement has been met partly, adequately or to the fullest extent at a reasonably affordable price.

Where the patent has not been worked in India during the relevant financial year, the form requires the patentee to state the reasons for non-working and the steps being taken to work the patent or the reasons why it is not possible or practicable to work the patent in India. This requirement to justify non-working is one of the most significant aspects of the Form 27 obligation it forces patent holders to confront and articulate their working strategy or its absence and it creates a documented record that can be used in subsequent compulsory licence proceedings.

The requirement to disclose the value of the patented product manufactured in India and imported from other countries is commercially sensitive information that many multinational patent holders have been reluctant to disclose. The Patents (Amendment) Rules, 2016 strengthened this requirement and there have been ongoing debates about the scope and precision of the disclosure required. Advocacy groups and generic pharmaceutical manufacturers have argued that the Form 27 disclosures should be more detailed and should be made publicly available in a searchable format to enable effective monitoring of patent working. Patent holder groups have argued that the disclosure requirements are disproportionately burdensome and that commercially sensitive revenue information should not be publicly accessible. This tension has not been fully resolved and the Form 27 regime continues to evolve through rule-making and administrative practice.

Consequences of Non-Working The Compulsory Licensing Framework

The most significant consequence of the non-working of a patent in India is the vulnerability of the patent to a compulsory licence application under Section 84. As discussed in earlier articles on this platform, Section 84 allows any person, after three years from the date of grant, to apply to the Controller for a compulsory licence on any of three grounds that the reasonable requirements of the public have not been satisfied, that the patented invention is not available to the public at a reasonably affordable price or that the patented invention is not being worked in the territory of India. The third ground directly and expressly targets non-working and the Form 27 disclosures or the absence of them provide the evidentiary foundation for a compulsory licence application on this ground.

The relationship between the Form 27 obligation and the compulsory licence framework is one of functional complementarity. Form 27 creates the documentary record of working or non-working that informs both the Controller’s assessment of compulsory licence applications and the applicant’s ability to establish the non-working ground. A patentee whose Form 27 filings consistently show zero manufacturing in India or who has failed to file Form 27 at all, is significantly more vulnerable to a successful compulsory licence application than one whose filings demonstrate active local manufacture and broad public availability at affordable prices.

Bayer Corporation v. Natco Pharma Ltd. The Working Requirement in Action

The most consequential application of the working requirement in Indian patent history is the compulsory licence granted in Bayer Corporation v. Natco Pharma Ltd., decided by the Controller of Patents in 2012 and upheld by the IPAB in 2013. Bayer held a patent over Sorafenib Tosylate brand name Nexavar used in the treatment of advanced kidney and liver cancer and was supplying the Indian market entirely through imports. Natco Pharma applied for a compulsory licence on all three grounds under Section 84, including the ground that the patent was not being worked in India.

The Controller, in a decision of landmark significance, granted the compulsory licence and held as confirmed by the IPAB that Bayer’s supply of the Indian market through imports did not constitute working of the patent in India within the meaning of the Act. The Controller held, in direct application of the principle in Section 83, that working requires local manufacture in India and not merely the making available of the product through importation. Bayer’s argument that it was commercially impractical to manufacture in India was rejected, the Controller holding that commercial inconvenience to the patentee is not a ground for excusing the working obligation where the public interest in local manufacture has not been satisfied.

This decision gave the working requirement real teeth for the first time in Indian patent history and demonstrated that the Form 27 mechanism which had been widely criticised as a toothless administrative exercise could provide the evidentiary foundation for a successful compulsory licence application with significant commercial consequences. The royalty fixed by the Controller at six percent of net sales was upheld by the IPAB and the decision sent a clear signal to multinational pharmaceutical companies holding Indian patents that a strategy of supply through importation without local manufacture carries serious legal risk.

Natco Pharma Ltd. v. Bristol-Myers Squibb Further Development of Working Jurisprudence

In Natco Pharma Ltd. v. Bristol-Myers Squibb Holdings Ireland, Natco applied for a compulsory licence over BMS’s patent for Dasatinib, a drug used to treat chronic myeloid leukaemia, arguing among other grounds that the patent was not being adequately worked in India. While this application was ultimately not granted on the same terms as the Bayer decision, the proceedings further developed the jurisprudence around what constitutes adequate working and the evidentiary standards applicable to Form 27 disclosures in compulsory licence proceedings. The case reinforced the principle that the Controller will examine the Form 27 filings of the patentee in detail and will assess the working status of the patent against the actual public health need for the patented product in India.

Lee Pharma Ltd. v. AstraZeneca AB The Limits of Compulsory Licensing

As discussed in the context of compulsory licensing, the Controller’s decision in Lee Pharma Ltd. v. AstraZeneca AB (2016) also engaged with the working requirement, holding that Lee Pharma had not adequately demonstrated that AstraZeneca’s patent for Saxagliptin was not being worked in India to the extent required to trigger the Section 84 ground. The decision illustrates the principle that the non-working ground under Section 84, while potentially powerful, requires the applicant to establish non-working with specific evidence it is not sufficient merely to point to the existence of the patent and the absence of local manufacture without addressing the patentee’s Form 27 disclosures and demonstrating that those disclosures reveal inadequate working.

The Public Interest Dimension Section 83 and the TRIPS Framework

The working requirement and the Form 27 obligation sit at the intersection of Indian domestic policy and international treaty obligations in a manner that has been the subject of sustained debate. The TRIPS Agreement, under Article 27.1, provides that patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced. This provision has been interpreted by the pharmaceutical industry as prohibiting any requirement of local manufacture as a condition of patent enjoyment a reading that is directly in tension with India’s working requirement as interpreted in the Bayer decision.

India’s position, supported by a number of developing country governments and by international trade law scholars, is that TRIPS Article 27.1 addresses discrimination in the availability of patents who can obtain patents and in what fields rather than the conditions under which granted patents must be worked and that the working requirement and compulsory licensing provisions of Sections 83, 84 and 89 are consistent with TRIPS Article 31’s express authorisation of compulsory licensing. This interpretation has not been definitively resolved at the WTO level no WTO dispute has ever directly challenged India’s working requirement and it remains one of the most contested doctrinal questions in international IP law.

The TRIPS Agreement’s Article 7 and Article 8 the objectives and principles provisions provide the interpretive context within which India’s working requirement should be understood. Article 8 expressly permits members to adopt measures necessary to protect public health and nutrition and to promote the public interest in sectors of vital importance to their socio-economic and technological development, provided such measures are consistent with the Agreement. India’s working requirement, understood as a measure designed to ensure that patented technology is transferred to and commercialised within India rather than merely supplied through imports, is a legitimate exercise of the flexibility that Article 8 preserves.

Ongoing Reform The 2023 Draft Patent Amendment Rules

The Indian government has periodically revisited the Form 27 framework in recognition of its limitations and of the gap between the obligation’s formal requirements and its practical enforcement. The draft Patents (Amendment) Rules, 2023 proposed significant changes to the Form 27 requirements, including more detailed disclosure of revenue figures, the value of licences granted, the number of units manufactured and sold in India and information about the accessibility of the patented product to the public. These proposals have been the subject of extensive consultation and debate, with generic manufacturers and public health advocates supporting stronger disclosure requirements and patentee groups arguing that the proposed disclosures are disproportionately burdensome and commercially sensitive.

The reform debate reflects a broader tension in Indian patent policy between the aspiration to attract pharmaceutical and technology investment by offering a predictable and internationally aligned patent system and the aspiration to ensure that the patent system serves domestic development objectives by requiring meaningful local working of patented technology. This tension is not unique to India it reflects the fundamental challenge of designing a patent system that serves both private incentive and public interest functions simultaneously but it has particular intensity in the Indian context given the country’s history as a supplier of affordable medicines to the developing world and its growing ambitions as a domestic innovation economy.

Consequences of False Statements in Form 27

Beyond the consequences of non-filing, the filing of false or misleading information in Form 27 carries independent legal consequences under Section 122 of the Patents Act. A patentee who files a Form 27 statement that misrepresents the extent of working for instance, by inflating the value of local manufacture, by characterising imports as local production or by omitting licensed working from the disclosure commits a statutory offence and is liable to a fine of up to ten lakh rupees. The provision has not been extensively enforced in practice, but its existence creates a legal framework within which the accuracy of Form 27 disclosures can be challenged whether by competitors, by the Controller in the course of examining a compulsory licence application or by the courts in the course of revocation or infringement proceedings in which the working status of the patent is relevant.

Practical Guidance for Patent Holders

For patent holders whether Indian companies, multinational corporations or research institutions the Form 27 obligation and the working requirement create a set of practical imperatives that must be integrated into patent portfolio management strategy. Every granted Indian patent requires a Form 27 filing for every financial year in which it is in force, regardless of whether it is being actively exploited. The filing must be accurate, detailed and consistent with the patentee’s actual commercial activities in India. Where a patent is not being worked in India, the reasons for non-working must be stated and those reasons should be genuine and defensible not mere boilerplate that will not withstand scrutiny in a subsequent compulsory licence proceeding.

Patent holders who supply the Indian market through imports rather than local manufacture should be acutely aware of the risk that this strategy creates under the Bayer jurisprudence. Where local manufacture is commercially impractical, the patentee should consider whether a licensing arrangement with an Indian manufacturer which would constitute working through a licensee is feasible and whether the terms of such a licence would satisfy the reasonable requirements of the public at an affordable price. A voluntary licence to an Indian generic manufacturer, at appropriate terms, is both a more commercially predictable and a more legally defensible strategy than relying on the defence of commercial impracticality against a compulsory licence application.

Conclusion

The working of patents framework in India encompassing the general principles of Section 83, the mandatory disclosure obligation of Section 146, the Form 27 filing requirement and the compulsory licensing consequences of non-working under Section 84 is one of the most distinctive and consequential features of Indian patent law. It reflects a legislative philosophy that grants patents not as unconditional property rights but as conditional monopolies, subject to ongoing obligations of public service whose non-performance carries real and enforceable legal consequences. The Bayer compulsory licence demonstrated that these consequences are not theoretical they are operational, commercially significant and enforceable against the largest pharmaceutical companies in the world.

For patent holders operating in India, the working requirement is not a compliance exercise to be managed minimally it is a strategic dimension of patent portfolio management that must be addressed with the same seriousness as the prosecution and enforcement of patent rights. The Form 27 obligation is not merely a regulatory filing but a declaration of the patentee’s commercial relationship with the Indian public a declaration whose accuracy and substance will be scrutinised whenever the working status of the patent becomes legally relevant. In a patent system designed, as Section 83 expressly declares, to ensure that inventions are worked in India on a commercial scale for the benefit of the public, the obligation to work is not a condition of the bargain it is the bargain itself.

References

The Patents Act, 1970 https://ipindia.gov.in
The Patents Rules, 2003 (including 2016 Amendment) https://ipindia.gov.in
Bayer Corporation v. Natco Pharma Ltd., Controller of Patents, 2012; IPAB, 2013 https://ipindia.gov.in
Lee Pharma Ltd. v. AstraZeneca AB, Controller of Patents, 2016 https://ipindia.gov.in
Manual of Patent Office Practice and Procedure https://ipindia.gov.in
TRIPS Agreement, WTO https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
National IPR Policy, 2016, DPIIT https://dpiit.gov.in
Draft Patents Amendment Rules, 2023, DPIIT https://dpiit.gov.in
Indian Patent Office Official Portal https://ipindia.gov.in
Competition Commission of India https://cci.gov.in

Working of Patents in India – Section 83, Form 27 and Consequences

Leave a Comment Cancel Reply